Antimicrobial Drugs

Learning Objectives

• Classify antibiotics by mechanism of action (cell wall, protein synthesis, nucleic acid, cell membrane, metabolic pathway)
• Explain the beta-lactam mechanism and why beta-lactamase production defeats it
• Distinguish bactericidal from bacteriostatic action and know why the distinction matters clinically
• Match major antibiotic, antifungal, and antiviral classes to their prototype drugs and targets
• Describe the four core mechanisms of antimicrobial resistance
• Apply drug-bug matching logic to predict a reasonable empirical choice for a given infection

Quick Answer

Antimicrobial drugs kill or inhibit bacteria, fungi, viruses, or parasites by exploiting biological differences between the pathogen and the human host. Antibiotics attack bacterial-specific targets — the cell wall, ribosomes, DNA gyrase, or folate synthesis. Antifungals target the fungal cell membrane (ergosterol) or cell wall, structures human cells lack or build differently. Antivirals block steps unique to viral replication, since viruses hijack host machinery and leave few purely viral targets. The unifying exam theme is selective toxicity: the more a drug's target differs from the human equivalent, the safer and more effective it is — and the mechanism of action almost always predicts both the drug's side-effect profile and how bacteria evolve resistance to it.

Antibiotic Classification by Mechanism of Action

Grouping antibiotics by what they attack rather than by chemical family is the fastest way to remember them, because mechanism drives spectrum, resistance, and toxicity.

Cell Wall Synthesis Inhibitors (Bactericidal)

Beta-lactams (penicillins, cephalosporins, carbapenems, monobactams) are the largest and most exam-heavy class. Bacterial cell walls are built from peptidoglycan, cross-linked by enzymes called penicillin-binding proteins (PBPs). Beta-lactams have a four-membered beta-lactam ring that structurally mimics the D-Ala-D-Ala terminus of the peptidoglycan chain. PBPs bind the drug instead of the natural substrate, get permanently inactivated, cross-linking stops, and the weakened wall lyses under osmotic pressure — the drug is bactericidal only against actively dividing cells, because a cell that isn't building new wall has nothing to disrupt.

• Penicillins: Penicillin G/V (streptococci, syphilis), Amoxicillin/Ampicillin (extended gram-negative cover), Piperacillin-tazobactam (broad, antipseudomonal, protected by a beta-lactamase inhibitor)
• Cephalosporins: generation number roughly tracks increasing gram-negative and decreasing gram-positive coverage — 1st gen (Cefazolin, skin/surgical prophylaxis) → 3rd gen (Ceftriaxone, meningitis/gonorrhea) → 4th/5th gen (Cefepime, Ceftaroline, cover Pseudomonas or MRSA)
• Carbapenems (Meropenem, Imipenem): broadest gram-negative and gram-positive cover, reserved for resistant infections
• Monobactams (Aztreonam): gram-negative only, safe in true penicillin anaphylaxis since it doesn't cross-react

Glycopeptides: Vancomycin binds the D-Ala-D-Ala terminus directly (rather than the PBP enzyme), blocking cross-linking by steric hindrance. It's a large molecule that can't cross the outer membrane of gram-negative bacteria, so it only works against gram-positives — including MRSA, where beta-lactams fail because the organism expresses an altered PBP (PBP2a) that beta-lactams can't bind.

Protein Synthesis Inhibitors

Bacterial ribosomes (70S, made of 30S + 50S subunits) differ structurally from human 80S ribosomes — this is the selective-toxicity target.

• 30S inhibitors: Aminoglycosides (Gentamicin, Tobramycin) cause misreading of mRNA — bactericidal, but nephrotoxic and ototoxic, requiring peak/trough monitoring. Tetracyclines (Doxycycline) block tRNA binding to the A site — bacteriostatic, avoided in children and pregnancy due to teeth staining and bone growth effects.
• 50S inhibitors: Macrolides (Azithromycin, Erythromycin) block the translocation step — bacteriostatic, useful for atypical pneumonia (Mycoplasma, Chlamydia, Legionella) because they penetrate cells well. Clindamycin blocks peptide bond formation and is notorious for triggering C. difficile colitis. Linezolid blocks the initiation complex and is a last-line agent against resistant gram-positives (VRE, MRSA). Chloramphenicol is bacteriostatic and causes aplastic anemia and gray baby syndrome.

The bactericidal/bacteriostatic distinction matters most when the host's immune system can't finish the job — in neutropenic or immunocompromised patients, bacteriostatic drugs that merely halt growth may not be enough, and bactericidal agents are preferred.

Nucleic Acid Synthesis Inhibitors

• Fluoroquinolones (Ciprofloxacin, Levofloxacin) inhibit DNA gyrase (topoisomerase II) in gram-negatives and topoisomerase IV in gram-positives, preventing DNA supercoiling and replication — bactericidal. Associated with tendon rupture and QT prolongation.
• Rifampin binds bacterial RNA polymerase, blocking transcription — key drug in TB regimens, notorious enzyme inducer (reduces efficacy of oral contraceptives, warfarin) and turns body fluids orange.
• Metronidazole is reduced inside anaerobic organisms to a reactive form that causes DNA strand breaks — active against anaerobes and protozoa (Giardia, Trichomonas, Entamoeba), and causes a disulfiram-like reaction with alcohol.

Cell Membrane Disruptors

Polymyxins (Colistin) act as detergents on the bacterial outer membrane, causing leakage of cell contents — reserved for multidrug-resistant gram-negatives because of significant nephrotoxicity.

Folate Pathway Inhibitors (Sequential Blockade)

Bacteria must synthesize their own folate (they can't take up dietary folate like humans can), making this pathway an excellent selective target.

• Sulfonamides (Sulfamethoxazole) competitively inhibit dihydropteroate synthase
• Trimethoprim inhibits the next enzyme, dihydrofolate reductase

Given together as TMP-SMX (co-trimoxazole), they block two sequential steps of the same pathway — a synergistic combination classically used for UTIs and Pneumocystis jirovecii pneumonia prophylaxis in HIV patients.

Antifungals

Fungal cells are eukaryotic like human cells, which is exactly why antifungals are harder to design safely than antibiotics — there are fewer purely fungal-specific targets, and the main one is ergosterol, the fungal equivalent of human cholesterol in the cell membrane.

• Polyenes (Amphotericin B): bind ergosterol directly and punch pores in the fungal membrane — fungicidal, extremely effective against systemic mycoses, but notoriously nephrotoxic ("amphoterrible") because it has some affinity for human cholesterol too
• Azoles (Fluconazole, Voriconazole, Itraconazole): inhibit the fungal cytochrome P450 enzyme (14-alpha-demethylase) that converts lanosterol to ergosterol — fungistatic, and because they interact with a P450 enzyme, they're notorious for drug interactions via the human hepatic CYP450 system too
• Echinocandins (Caspofungin, Micafungin): inhibit beta-(1,3)-glucan synthase, blocking synthesis of the fungal cell wall — a target humans don't have at all (no cell wall), making this class one of the best-tolerated antifungal options, used mainly for invasive Candida and Aspergillus infections
• Terbinafine: inhibits squalene epoxidase (earlier step in ergosterol synthesis) — used for dermatophyte (skin/nail) infections
• Flucytosine: converted inside fungal cells to 5-fluorouracil, disrupting fungal RNA/DNA synthesis; usually paired with amphotericin B for cryptococcal meningitis

Antivirals

Viruses replicate using host-cell machinery, so most antivirals target the few enzymes that are virus-specific.

• Nucleoside/nucleotide analogs (Acyclovir, Zidovudine, Tenofovir): mimic natural nucleosides, get incorporated into replicating viral DNA/RNA by the viral polymerase, and cause chain termination. Acyclovir is activated only inside infected cells by a viral thymidine kinase — this selectivity is why it's so safe.
• Reverse transcriptase inhibitors: Zidovudine and Lamivudine (nucleoside RT inhibitors) act as chain terminators for HIV's reverse transcriptase; Nevirapine (non-nucleoside RT inhibitor) binds the enzyme at a separate site.
• Protease inhibitors (Ritonavir, Lopinavir): block the HIV protease that cleaves viral polyproteins into functional pieces, producing non-infectious immature virions.
• Integrase inhibitors (Dolutegravir): block integration of viral DNA into the host genome.
• Fusion/entry inhibitors (Enfuvirtide, Maraviroc): prevent the virus from entering the host cell in the first place.
• Neuraminidase inhibitors (Oseltamivir): block release of new influenza virions from infected cells by preventing cleavage of sialic acid.

Mechanisms of Antimicrobial Resistance

This is one of the highest-yield exam concepts because every resistance story fits one of four boxes:

1. Enzymatic drug inactivation — beta-lactamases hydrolyze the beta-lactam ring (the classic example); aminoglycoside-modifying enzymes add chemical groups that block ribosome binding
2. Target modification — MRSA's altered PBP2a no longer binds beta-lactams; fluoroquinolone resistance from mutated DNA gyrase
3. Decreased uptake / increased efflux — porin loss in the outer membrane keeps drugs out; efflux pumps actively export the drug once it enters (seen with tetracyclines and fluoroquinolones)
4. Metabolic bypass — some resistant bacteria acquire an alternative enzyme that isn't inhibited by the drug (e.g., an altered dihydropteroate synthase that evades sulfonamides)

Resistance genes spread between bacteria via plasmids, transposons, and conjugation — which is why overuse of any single antibiotic class can produce resistant organisms far beyond the original patient.

Uses and Indications

• Respiratory tract infections (pneumonia, bronchitis)
• Skin and soft tissue infections
• Urinary tract infections
• Sexually transmitted infections
• Malaria and other parasitic diseases
• Viral infections (HIV, influenza, herpes simplex)
• Surgical and endocarditis prophylaxis

Side Effects and Adverse Reactions

Every major toxicity pattern traces back to the drug's mechanism or off-target binding:

• Beta-lactams: hypersensitivity/anaphylaxis (immune-mediated, not dose-related)
• Aminoglycosides: nephrotoxicity, ototoxicity (accumulate in renal tubular cells and inner ear hair cells)
• Fluoroquinolones: tendon rupture, QT prolongation
• Vancomycin: "red man syndrome" from rapid infusion (histamine release, not a true allergy), nephrotoxicity
• Amphotericin B: infusion-related fever/chills, nephrotoxicity
• Clindamycin, broad-spectrum agents in general: C. difficile colitis from disrupting normal gut flora
• Broad-spectrum antifungal/antibacterial overuse: Candida superinfection

Resistance and Stewardship

Antimicrobial stewardship means choosing the narrowest effective agent, the correct dose and duration, and de-escalating once culture results return. This limits selection pressure that drives resistance and preserves last-line agents (carbapenems, vancomycin, colistin) for when nothing else works.

Key Terms

Term	Definition
Selective toxicity	The principle that a drug harms the pathogen more than the host by exploiting a target the pathogen has and the host lacks or differs in
Bactericidal	Kills bacteria outright (e.g., beta-lactams, aminoglycosides, fluoroquinolones)
Bacteriostatic	Halts bacterial growth, relying on host immunity to clear the infection (e.g., macrolides, tetracyclines)
Beta-lactamase	Bacterial enzyme that hydrolyzes the beta-lactam ring, inactivating penicillins/cephalosporins
Penicillin-binding protein (PBP)	Bacterial enzyme that cross-links peptidoglycan; the target of beta-lactam antibiotics
Ergosterol	Fungal membrane sterol equivalent to human cholesterol; the target of polyenes and azoles
Minimum inhibitory concentration (MIC)	Lowest drug concentration that visibly inhibits bacterial growth in vitro; guides dosing
Empirical therapy	Antibiotic choice made before culture results are available, based on likely pathogens
Superinfection	A new infection (often fungal, e.g., Candida) that emerges after broad-spectrum antimicrobials wipe out normal flora
Efflux pump	Membrane transporter that actively pumps a drug out of the bacterial cell, a resistance mechanism

Common Mistakes

Misconception 1: "Antibiotics work against viruses too if the infection is severe enough." Why it's wrong: Antibiotics target bacterial-specific structures (cell wall, bacterial ribosomes, bacterial enzymes) that viruses simply don't have — a virus has no cell wall to attack and uses the host's own ribosomes. Correct understanding: Antibiotics are useless against viral infections regardless of severity; only antivirals target virus-specific replication steps, and giving antibiotics for a viral illness only adds resistance pressure without benefit.

Misconception 2: "Bactericidal drugs are always superior to bacteriostatic drugs." Why it's wrong: The label describes the drug's mechanism, not overall clinical superiority — in an immunocompetent patient, halting bacterial growth (bacteriostatic) gives the immune system enough time to clear the infection just as effectively. Correct understanding: Bactericidal agents are specifically preferred in situations where the host's defenses can't help — neutropenia, endocarditis, meningitis — not as a universal rule of "better."

Misconception 3: "Higher generation cephalosporins are always more potent." Why it's wrong: Generation number tracks a shift in spectrum (more gram-negative, less gram-positive coverage as you move from 1st to later generations), not a linear increase in overall strength. Correct understanding: A 1st-generation cephalosporin like cefazolin is actually the better choice for a straightforward staphylococcal skin infection or surgical prophylaxis than a 3rd-generation agent like ceftriaxone, which is reserved for gram-negative or CNS-penetrating indications.

Comparison and Connections

Feature	Antibiotics	Antifungals	Antivirals
Target cell type	Prokaryotic (bacteria)	Eukaryotic (fungi)	Uses host eukaryotic machinery
Key selective target	Cell wall (peptidoglycan), 70S ribosome	Ergosterol, fungal cell wall (beta-glucan)	Virus-specific enzymes (polymerase, protease, integrase)
Why fewer safe drugs exist	Bacterial structures differ greatly from human cells	Fungal cells resemble human cells, fewer unique targets	Viruses hijack host cells, very few purely viral targets
Classic resistance route	Beta-lactamase, PBP mutation, efflux pumps	Efflux pumps, altered ergosterol targets (less common)	Rapid mutation of viral polymerase/protease (esp. HIV, influenza)
Cidal example	Penicillin (cell wall)	Amphotericin B (membrane pore)	Acyclovir (chain termination)
Static example	Erythromycin (protein synthesis)	Fluconazole (ergosterol synthesis block)	— (most are considered virustatic, relying on host clearance)

Practice Questions

Recall

1. Name the two enzymes that TMP-SMX inhibits and state which drug inhibits which. Answer guidance: Sulfamethoxazole inhibits dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase — both steps in bacterial folate synthesis.
2. Which antifungal class inhibits beta-(1,3)-glucan synthase, and why does this make it particularly well tolerated? Answer guidance: Echinocandins (e.g., caspofungin); well tolerated because beta-glucan is part of the fungal cell wall, a structure human cells don't have at all.

Understanding

3. Explain why beta-lactam antibiotics only kill actively dividing bacteria. Answer guidance: They inhibit PBPs that cross-link new peptidoglycan during cell wall synthesis; a non-dividing cell isn't building new wall, so there's nothing for the drug to disrupt.
4. Why do azole antifungals cause so many drug-drug interactions? Answer guidance: They inhibit fungal cytochrome P450 (14-alpha-demethylase), and because this enzyme family is closely related to the human hepatic CYP450 enzymes that metabolize many other drugs, azoles also inhibit human CYP450, slowing clearance of co-administered medications.

Application

5. A patient with MRSA bacteremia is not responding to a beta-lactam. Explain the resistance mechanism and name an appropriate alternative drug class. Answer guidance: MRSA expresses PBP2a, an altered penicillin-binding protein with low affinity for beta-lactams, so the drug can't bind its target; vancomycin (or linezolid) is an appropriate alternative since it binds the D-Ala-D-Ala peptidoglycan terminus directly rather than the PBP enzyme.
6. A patient on rifampin for tuberculosis is also taking oral contraceptives. What interaction should be anticipated and why? Answer guidance: Rifampin is a potent inducer of hepatic CYP450 enzymes, which accelerates metabolism of the contraceptive hormones and can lead to contraceptive failure — an alternative or additional contraceptive method should be discussed.

Analysis

7. Compare why selective toxicity is easier to achieve with antibacterial drugs than with antifungal drugs. Answer guidance: Bacteria are prokaryotic with structurally distinct targets (peptidoglycan wall, 70S ribosomes, unique enzymes) entirely absent or different from human cells, while fungi are eukaryotic and share many structural and biochemical features with human cells, leaving fewer fungus-only targets (mainly ergosterol and the fungal cell wall) — hence antifungals tend to have narrower margins of safety.
8. A clinician is choosing between a bactericidal and bacteriostatic agent for a febrile neutropenic patient. Justify the better choice. Answer guidance: A bactericidal agent is preferable because the patient's own neutrophils (needed to finish off bacteria weakened by a bacteriostatic drug) are critically low, so the drug itself must eliminate the organism rather than relying on host immune clearance.

FAQ

1. Why don't antibiotics work on colds or flu? Colds and flu are caused by viruses, and antibiotics target bacterial structures (cell walls, bacterial ribosomes) that simply don't exist in a virus. Taking antibiotics for a viral illness provides no benefit and only encourages resistant bacteria to develop elsewhere in your body.

2. What's the practical difference between bactericidal and bacteriostatic drugs? Bactericidal drugs actively kill bacteria; bacteriostatic drugs stop them from multiplying and rely on the immune system to clear the rest. In a healthy immune system both approaches usually work, but in immunocompromised patients bactericidal drugs are preferred.

3. Why is amphotericin B so toxic if it targets a fungus-specific molecule? Amphotericin B binds ergosterol very effectively, but it has some residual affinity for human cholesterol, which is structurally similar. That off-target binding in kidney cell membranes is the main driver of its notorious nephrotoxicity.

4. How does bacterial resistance actually spread between different bacteria? Resistance genes are frequently carried on plasmids or transposons — mobile pieces of DNA that can transfer between bacteria (even different species) through conjugation, independent of normal reproduction. This is why one resistant strain can seed resistance across a whole hospital ward.

5. Why do doctors need to "match the drug to the bug" instead of just using one broad-spectrum antibiotic for everything? Broad-spectrum agents kill normal protective flora along with the pathogen, raising the risk of superinfections like C. difficile or Candida, and heavy broad-spectrum use accelerates resistance. Narrow, targeted therapy based on culture and sensitivity results is safer for the patient and for future patients who might face the same organism.

Quick Revision

• Selective toxicity is the core principle: attack a target the pathogen has that the host doesn't (or has differently)
• Beta-lactams inhibit PBPs that cross-link peptidoglycan; work only on actively dividing bacteria
• Beta-lactamase enzymes are the classic beta-lactam resistance mechanism; MRSA instead uses an altered PBP2a
• Aminoglycosides and tetracyclines hit the 30S ribosomal subunit; macrolides, clindamycin, linezolid hit the 50S subunit
• Fluoroquinolones block DNA gyrase/topoisomerase IV; rifampin blocks RNA polymerase; metronidazole causes DNA strand breaks in anaerobes
• TMP-SMX is a synergistic sequential blockade of two folate-synthesis enzymes
• Four resistance mechanisms: enzymatic inactivation, target modification, decreased uptake/efflux, metabolic bypass
• Antifungals target ergosterol (polyenes, azoles) or the fungal cell wall (echinocandins) — fewer unique targets than bacteria because fungi are eukaryotic
• Amphotericin B is fungicidal but nephrotoxic; echinocandins are among the best-tolerated because humans lack a cell wall entirely
• Most antivirals are nucleoside analogs or target virus-specific enzymes (protease, integrase, reverse transcriptase) since viruses use host machinery for everything else
• Bactericidal is preferred over bacteriostatic when host immunity can't help (neutropenia, endocarditis, meningitis)
• Antimicrobial stewardship (narrowest effective drug, correct duration, de-escalation) is the main tool against resistance

Related Topics

Prerequisites

• Basic bacterial cell structure (cell wall, ribosomes, plasmids)
• General pharmacokinetics and pharmacodynamics principles

Related Topics

• Infectious disease syndromes (pneumonia, UTI, meningitis) and their typical causative organisms
• Vaccines and immunology
• Antimicrobial stewardship and hospital infection control

Next Topics

• Chemotherapy and anticancer drugs (another selective-toxicity based drug class)
• Clinical microbiology: culture, sensitivity testing, and MIC interpretation